publication venue for
- Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma. 2019
- Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer.. 7. 2023
- Development and testing of a polygenic risk score for breast cancer aggressiveness.. 7. 2023
- Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway.. 7. 2023
- Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations.. 7. 2023
- MatchMiner: an open-source platform for cancer precision medicine.. 6. 2022
- Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib.. 6. 2022
- The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer.. 6. 2022
- Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome.. 6. 2022
- Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade.. 6. 2022
- Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.. 5. 2021
- A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors.. 5. 2021
- Preoperative clinical and tumor genomic features associated with pathologic lymph node metastasis in clinical stage I and II lung adenocarcinoma.. 5. 2021
- Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia.. 5. 2021
- Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study.. 5. 2021
- Decreased cytotoxic T cells and TCR clonality in organ transplant recipients with squamous cell carcinoma.. 4. 2020
- Author Correction: Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.. 5. 2021